Cold Plasma Histone mRNA Degradation for Selective Breast Cancer Cell Death
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for breast cancer, including cold atmospheric plasma (CAP), lack a clear understanding of the mechanism by which they selectively induce cell death in cancer cells while sparing normal tissue, with RNA's role in this process remaining unexplored.
Innovation Solution
Cold plasma treatment induces cell death in breast cancer cells by degrading histone mRNA through 8-oxoG modification during the early S-phase of the cell cycle, specifically targeting histone mRNA types, as demonstrated by RNASeq profiling and qRT-PCR analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cold atmospheric plasma is used to treat breast cancer cells, then cell death is induced, but the mechanism of selective targeting remains unclear
Solution Approach 1:
The patent identifies histone mRNA as an intermediary molecule that mediates the selective cell death effect of cold atmospheric plasma. The plasma treatment causes oxidation of histone mRNA through reactive oxygen species, leading to degradation of this critical mRNA and subsequent cell death. This intermediary mechanism explains the selectivity observed in the treatment.
Solution Approach 2:
The patent utilizes parameter changes in the cell cycle (specifically the S-phase when histone mRNA is most abundant) to achieve selective targeting. By timing the plasma treatment to coincide with S-phase when cancer cells are actively synthesizing histone mRNA, the treatment maximizes oxidation and degradation of this mRNA, leading to selective cell death in proliferating cancer cells while sparing non-proliferating normal cells.
2Productivity
If cold plasma targets histone mRNA during S-phase, then cancer cell death is achieved, but normal tissue protection mechanism is not fully understood
Solution Approach 1:
The patent exploits the dynamic nature of the cell cycle, specifically the temporal variation in histone mRNA abundance. During S-phase, histone mRNA levels are high in proliferating cells, making them vulnerable to plasma-induced oxidation. In non-proliferating normal cells, histone mRNA levels remain low throughout the cell cycle, providing natural protection. This dynamic targeting approach enables selective cancer cell elimination while preserving normal tissue.
3Measurement precision
If RNA oxidation is the primary mechanism, then selective degradation occurs, but the specificity to histone mRNA needs verification
Solution Approach 1:
The patent demonstrates local quality in terms of mRNA type specificity. While cold atmospheric plasma can oxidize various RNA molecules, the patent shows that histone mRNA is particularly vulnerable due to its high abundance during S-phase and specific structural characteristics. The oxidation and degradation are localized to histone mRNA rather than affecting all mRNA types equally, providing the observed selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This mechanism effectively induces cell death in breast cancer cells across different subtypes, with histone mRNA degradation being the primary cause, as shown by increased DNA damage responder gene expression and cell cycle arrest at the G1 phase.
Implementation Method 1
Cold plasma induced cell death is due to 8-oxoG RNA oxidation of histone RNA followed by degradation
Implementation Method 2
Cold atmospheric plasma (CAP) has shown promising results as an adjuvant therapy to selectively combat many cancers including breast cancer cells
Data Source
AI summary
A method for inducing cell death in breast cancer regardless of subtyping through histone mRNA oxidation and degradation during the early S-phase of the cell cycle. A method for monitoring levels of oxidized histone mRNA in breast cancer cells, comprising the steps of isolating histone mRNA from breast cancer cells, incubating the histone mRNA with a peptide according to SEQ ID NO: 1 and determining the levels of oxidized histone mRNA by measuring the fluorescence intensity.